No Data
Shanghai Rendu Biotechnology's (SHSE:688193) Solid Earnings May Rest On Weak Foundations
Third Quarter Report 2024
Rendu Biotechnology (688193.SH) released its performance for the first three quarters, with a net income of 4.67 million yuan, turning a loss into profit year-on-year.
RenDu Bio (688193.SH) disclosed the third quarter report of 2024, achieving revenue of 1....
Rendu Biotech (688193.SH): The net income for the first three quarters was 4.67 million yuan.
Green Link News on October 29th: RenDu Biological (688193.SH) released its third-quarter report, with revenue of 0.13 billion yuan in the first three quarters, an 11.57% year-on-year growth, net income of 4.67 million yuan, non-net loss of 3.17 million yuan, and basic earnings per share of 0.12 yuan.
Just One Day Till Shanghai Rendu Biotechnology Co., Ltd. (SHSE:688193) Will Be Trading Ex-Dividend
Rendu Biology (688193.SH) plans to distribute 1 yuan for every 10 shares in the first half of the year, with ex-rights and ex-dividend dates on October 30.
Announcement from Rendo Biotech (688193.SH), the company plans to distribute a cash dividend of 1 per 10 shares for the first half of 2024...
Shanghai Rendu Biotechnology Co., Ltd.'s (SHSE:688193) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
